Category

Archives

Bcl-2

Immune infiltration landscape on prognosis and therapeutic response and relevant epigenetic and transcriptomic mechanisms in lung adenocarcinoma

1 views | Nov 18 2022

Liangming Zhang et al. found that EXO1 facilitated PD-L1 and sPD-L1 expression in LUAD cells. [Read the Full Post]

BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer

2 views | Oct 03 2022

Prashanthi Ramesh et al. found a cell transferable induction of a FGF2/FGFR4 rescue response in CRC that was induced upon BCL-XL inhibition and lead to MCL-1 upregulation. [Read the Full Post]

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer

2 views | Oct 01 2022

Andrea Lopez et al. advanced the understanding of apoptosis resistance mechanisms and demonstrate a novel therapeutic strategy for cancer treatment. [Read the Full Post]

Single-Molecule Sensing of an Anticancer Therapeutic Protein-Protein Interaction Using the Chemically Modified OmpG Nanopore

59 views | Jul 02 2022

Hye-Jin Hwang et al. found that the chemically modified OmpG nanopore can serve as a valuable sensor platform for ultrasensitive, rapid, and single-molecule-based drug screening against protein-protein interactions, which are therapeutic targets for various diseases. [Read the Full Post]

BAK plays a key role in A-1331852-induced apoptosis in senescent chondrocytes

55 views | Jun 20 2022

Guihao Wu et al. found that A-1331852 selectively promoted apoptosis in senescent chondrocytes by interfering with the interaction between Bcl-xL and BAK. [Read the Full Post]

Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study

57 views | May 17 2022

Naveen Pemmaraju et al. revealed clinically meaningful splenic responses independent of high molecular risk mutation status in patients treated with navitoclax plus ruxolitinib who were not benefiting from ruxolitinib monotherapy. [Read the Full Post]

Targeting Apoptosis in ALL

62 views | May 17 2022

Wesley M Smith et al. showed that ALL depended on the BCL-2 family of proteins for cell survival and proliferation. [Read the Full Post]

Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax

80 views | May 15 2022

Hongcai Liu et al. found that the combination of BEZ235 and ABT199 exhibited a synergistic anti-tumor effect in AML by down-regulating MCL-1 protein. [Read the Full Post]

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

132 views | Apr 16 2022

Andrew J Armstrong et al.found that enzalutamide plus ADT significantly prolongs survival versus placebo plus ADT in patients with mHSPC. [Read the Full Post]

Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance

70 views | Apr 12 2022

Fangbing Liu et al. revealed that the combined inhibition of Mcl-1 and Bcl-2 showed promise against AML cells, including relapse/refractory AML. [Read the Full Post]